The German group has come late to antibody testing, but has punchy accuracy data and a possible means of neutralising some of the competition.
IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
The German start-up must navigate the hazards that have felled other surgical robot developers while simultaneously dealing with a more crowded market.
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
The group has the only approved cell-based cancer blood test in the world, but competing in an increasingly cutthroat market will be tough.